Preeclampsia remains one of the leading causes of maternal and perinatal mortality and morbidity worldwide. It is now the major cause of iatrogenic preterm birth in Australia. There have been no therapeutic advances in the management of preeclampsia for almost 50 years. The Group continues to explore fundamental mechanisms of maternal endothelial injury in preeclampsia with a view to the development of more effective therapies. The research involves in vitro studies, small animal models of preeclampsia, and clinical trials. A world first clinical trial of melatonin as an adjuvant therapy for preeclampsia is underway. The Group is also leading work on the role(s) of activin and other TGF family members in the pathogenesis of preeclampsia. Dr Bryan Leaw recently joined the group to establish a panel of pre-clinical models for therapeutic testing.
Professor Milton Hearn– Director, Centre for Bioprocess Technology, Department of Biochemistry and Molecular Biology
Associate Professor Grant Drummond – NHMRC Senior Research Fellow, Department of Pharmacology, Monash University
Associate Professor Chris Sobey – Department of Pharmacology, Monash University